目前针对青少年特发性关节炎的医学治疗方法。
Current medical treatments for juvenile idiopathic arthritis.
机构信息
Pediatria II e Reumatologia, Istituto G Gaslini Genoa, University of Genoa Genoa, Italy.
出版信息
Front Pharmacol. 2011 Oct 10;2:60. doi: 10.3389/fphar.2011.00060. eCollection 2011.
Abstract
Juvenile idiopathic arthritis (JIA) differs markedly from adult rheumatoid arthritis. It is not a single disease, but an exclusion diagnosis that gather together all forms of arthritis that begin before the age of 16 years, persist for more than 6 weeks, and are of unknown origin. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of therapies. The implementation of an adequate legislation as well as the presence of international research networks of pediatric rheumatology have contributed to foster the conduct of controlled clinical trials and the development of validated outcome measures. This review will currently describe the methodological approach for performing clinical trials in JIA as well as the current available drug treatment.
摘要
幼年特发性关节炎（JIA）与成人类风湿关节炎明显不同。它不是一种单一的疾病，而是一种排除性诊断，将所有在 16 岁之前发病、持续超过 6 周且病因不明的关节炎都归为这一类。新的生物治疗方法的出现极大地改变了治疗的反应和治疗的预期。适当的立法的实施以及儿科风湿病学的国际研究网络的存在，有助于促进对照临床试验的进行和验证有效的结果测量方法的发展。本文将目前描述在 JIA 中进行临床试验的方法学方法以及当前可用的药物治疗。
相似文献
1
Current medical treatments for juvenile idiopathic arthritis.目前针对青少年特发性关节炎的医学治疗方法。
Front Pharmacol. 2011 Oct 10;2:60. doi: 10.3389/fphar.2011.00060. eCollection 2011.
2
Emerging drugs to treat juvenile idiopathic arthritis.治疗幼年特发性关节炎的新兴药物。
Expert Opin Emerg Drugs. 2011 Sep;16(3):493-505. doi: 10.1517/14728214.2011.581662. Epub 2011 Apr 30.
3
Juvenile idiopathic arthritis: state of the art and future perspectives.幼年特发性关节炎：现状与未来展望。
Ann Rheum Dis. 2010 Jul;69(7):1260-3. doi: 10.1136/ard.2010.133033. Epub 2010 Jun 4.
4
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus.迈向幼年特发性关节炎新分类标准：初步步骤，儿科风湿病学国际试验组织国际共识。
J Rheumatol. 2019 Feb;46(2):190-197. doi: 10.3899/jrheum.180168. Epub 2018 Oct 1.
5
Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis.治疗幼年特发性关节炎的当前治疗选择
Curr Rheumatol Rev. 2021;17(1):41-57. doi: 10.2174/1573403X16999200917151805.
6
A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort.加拿大关节炎队列中儿童幼年特发性关节炎的国际风湿病联盟与儿科风湿病国际试验组织分类系统比较。
Arthritis Rheumatol. 2022 Aug;74(8):1409-1419. doi: 10.1002/art.42113. Epub 2022 Jun 28.
7
Current Validated Clinical and Patient Reported Disease Outcome Measures in Juvenile Idiopathic Arthritis.目前已验证的青少年特发性关节炎临床及患者报告的疾病结局指标
Open Access Rheumatol. 2023 Oct 9;15:189-206. doi: 10.2147/OARRR.S261773. eCollection 2023.
8
[JUVENILE IDIOPATHIC ARTHRITIS].[幼年特发性关节炎]
Reumatizam. 2016;63 Suppl 1:53-8.
9
Advances from clinical trials in juvenile idiopathic arthritis.幼年特发性关节炎的临床试验进展。
Nat Rev Rheumatol. 2013 Sep;9(9):557-63. doi: 10.1038/nrrheum.2013.105. Epub 2013 Jul 9.
10
[Change of diagnosis and diagnostic category in patients with juvenile idiopathic arthritis within 7 years of follow-up].[青少年特发性关节炎患者随访7年内诊断及诊断类别的变化]
Rev Chil Pediatr. 2020 Aug;91(4):521-528. doi: 10.32641/rchped.v91i4.1376. Epub 2020 Jun 23.
引用本文的文献
1
Assessing Methotrexate Adherence in Juvenile Idiopathic Arthritis Using Electronic Health Record-Linked Pharmacy Dispensing Data.利用与电子健康记录相关联的药房配药数据评估青少年特发性关节炎患者的甲氨蝶呤依从性。
Arthritis Care Res (Hoboken). 2025 Mar;77(3):300-308. doi: 10.1002/acr.25441. Epub 2024 Oct 25.
2
Examining the Relationship between Systemic Immune-Inflammation Index and Disease Severity in Juvenile Idiopathic Arthritis.探究全身免疫炎症指数与幼年特发性关节炎疾病严重程度之间的关系。
Cells. 2024 Mar 3;13(5):442. doi: 10.3390/cells13050442.
3
Maximum bite force in children with juvenile idiopathic arthritis with and without clinical established temporomandibular joint involvement and in healthy children: a cross-sectional study.儿童最大咬合力在青少年特发性关节炎且有和无临床确定的颞下颌关节受累者以及健康儿童中的比较：一项横断面研究。
J Oral Rehabil. 2021 Jul;48(7):774-784. doi: 10.1111/joor.13172. Epub 2021 May 4.
4
Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study.接受甲氨蝶呤或阿达木单抗治疗的少关节型和多关节型幼年特发性关节炎患者的外周血淋巴细胞分析：一项横断面研究
Front Pediatr. 2020 Dec 10;8:614354. doi: 10.3389/fped.2020.614354. eCollection 2020.
5
Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study.青少年特发性关节炎患儿及青少年生物制剂转换的频率和转换结果：一项全国队列研究
Lancet Rheumatol. 2020 Mar 9;2(4):e217-e226. doi: 10.1016/S2665-9913(20)30025-4. eCollection 2020 Apr.
6
Infliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China.英夫利昔单抗治疗中国多关节型幼年特发性关节炎患者的疗效及预后：一项单中心研究。
World J Pediatr. 2020 Feb;16(1):68-73. doi: 10.1007/s12519-019-00316-5. Epub 2019 Oct 14.
7
Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.临床幼年特发性关节炎疾病活动评分被证明是幼年特发性关节炎靶向治疗中的一种有用工具。
Ann Rheum Dis. 2018 Mar;77(3):336-342. doi: 10.1136/annrheumdis-2017-212104. Epub 2017 Nov 14.
8
Implementation of musculoskeletal ultrasonography in detection of early juvenile idiopathic arthritis.肌肉骨骼超声检查在早期幼年特发性关节炎检测中的应用
Eur J Radiol Open. 2016 Nov 21;3:264-271. doi: 10.1016/j.ejro.2016.11.001. eCollection 2016.
9
Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.髓样相关蛋白8/14和C反应蛋白的预处理水平较低预示着青少年特发性关节炎患者对肿瘤坏死因子抑制剂治疗的依从性较差。
Clin Rheumatol. 2017 Jan;36(1):67-75. doi: 10.1007/s10067-016-3375-x. Epub 2016 Aug 25.
10
[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].[成年早期幼年特发性关节炎的生物制剂治疗：从儿科护理向成人护理的过渡]
Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z.
本文引用的文献
1
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.一项评估卡那单抗治疗具有活动性全身症状的系统性幼年特发性关节炎的给药方案及初步安全性和有效性的II期多中心开放标签研究。
Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342.
2
Juvenile idiopathic arthritis.幼年特发性关节炎。
Lancet. 2011 Jun 18;377(9783):2138-49. doi: 10.1016/S0140-6736(11)60244-4.
3
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.2011 年美国风湿病学会治疗幼年特发性关节炎的建议：关节炎和全身表现治疗药物的起始治疗和安全性监测。
Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82. doi: 10.1002/acr.20460.
4
Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study.幼年特发性关节炎患者的疾病活动度、功能障碍和关节损伤分析：一项前瞻性结局研究。
Clin Exp Rheumatol. 2011 Mar-Apr;29(2):337-44. Epub 2011 Apr 19.
5
A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report.一种新的青少年特发性关节炎临床护理方法：青少年关节炎多维评估报告。
J Rheumatol. 2011 May;38(5):938-53. doi: 10.3899/jrheum.100930. Epub 2011 Mar 1.
6
Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO).儿科领域的交流：以儿科风湿病国际临床试验组织 (PRINTO) 为例。
Arch Dis Child. 2011 Jun;96(6):596-601. doi: 10.1136/adc.2010.188946. Epub 2011 Feb 12.
7
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.阿那白滞素作为全身型幼年特发性关节炎的一线改善病情治疗：来自一项国际多中心研究的46例患者报告
Arthritis Rheum. 2011 Feb;63(2):545-55. doi: 10.1002/art.30128.
8
Malignancies in juvenile idiopathic arthritis: a preliminary report.幼年特发性关节炎相关恶性肿瘤：初步报告。
J Rheumatol. 2011 Apr;38(4):760-3. doi: 10.3899/jrheum.100711. Epub 2011 Jan 15.
9
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).一项多中心、随机、双盲、安慰剂对照的临床试验，评估白细胞介素-1 受体拮抗剂阿那白滞素治疗全身型幼年特发性关节炎（ANAJIS 试验）。
Ann Rheum Dis. 2011 May;70(5):747-54. doi: 10.1136/ard.2010.134254. Epub 2010 Dec 20.
10
Report on malignancies in the German juvenile idiopathic arthritis registry.德国青少年特发性关节炎注册研究中的恶性肿瘤报告。
Rheumatology (Oxford). 2011 Jan;50(1):230-6. doi: 10.1093/rheumatology/keq361.
Zotero 插件